In February FDA officials admitted that they had never inspected Changzhou SPL, the manufacturing plant in Changzhou, China, to which they traced the contaminated heparin.

• 今年2月，美国FDA官员在追查受污染肝素来源当中承认，他们从来没有彻查过坐落在中国常州SPL制药工厂。